Skip to main content

Search

12 result(s) for 'author#Joseph Geradts' within BMC

Page 1 of 1

Sort by: Relevance | Date

  2. Residual cancer following breast conserving surgery increases the risk of local recurrence and mortality. Margin assessment presents an unmet clinical need. Breast tissue is markedly heterogeneous, which makes...

    Authors: Stephanie Kennedy, Joseph Geradts, Torre Bydlon, J Quincy Brown, Jennifer Gallagher, Marlee Junker, William Barry, Nimmi Ramanujam and Lee Wilke
    Citation: Breast Cancer Research 2010 12:R91
    Content type: Research article Published on:

  3. The normal human prostate glandular epithelium has the unique function of accumulating high levels of zinc. In prostate cancer this capability is lost as an early event in the development of the malignant cell...

    Authors: Mohamed M Desouki, Joseph Geradts, Beatrice Milon, Renty B Franklin and Leslie C Costello
    Citation: Molecular Cancer 2007 6:37
    Content type: Research Published on:

  4. Breast cancer is a heterogeneous disease, with several intrinsic subtypes differing by hormone receptor (HR) status, molecular profiles, and prognosis. However, the role of DNA methylation in breast cancer dev...

    Authors: Kathleen Conway, Sharon N Edmiston, Ryan May, Pei Fen Kuan, Haitao Chu, Christopher Bryant, Chiu-Kit Tse, Theresa Swift-Scanlan, Joseph Geradts, Melissa A Troester and Robert C Millikan
    Citation: Breast Cancer Research 2014 16:450
    Content type: Research article Published on:

  5. Activation status of the phosphatidylinositol 3-kinase (PI3K) pathway in breast cancer brain metastases (BCBMs) is largely unknown. We examined expression of phospho(p)-AKT, p-S6, and phosphatase and tensin ho...

    Authors: Barbara Adamo, Allison M Deal, Emily Burrows, Joseph Geradts, Erika Hamilton, Kimberly L Blackwell, Chad Livasy, Karen Fritchie, Aleix Prat, J Chuck Harrell, Matthew G Ewend, Lisa A Carey, C Ryan Miller and Carey K Anders
    Citation: Breast Cancer Research 2011 13:R125
    Content type: Research article Published on:

  6. Breast cancer subtype can be classified using standard clinical markers (estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)), supplemented with additional ma...

    Authors: Emma H. Allott, Joseph Geradts, Stephanie M. Cohen, Thaer Khoury, Gary R. Zirpoli, Wiam Bshara, Warren Davis, Angela Omilian, Priya Nair, Rochelle P. Ondracek, Ting-Yuan David Cheng, C. Ryan Miller, Helena Hwang, Leigh B. Thorne, Siobhan O’Connor, Traci N. Bethea…
    Citation: Breast Cancer Research 2018 20:12
    Content type: Research Article Published on:

  7. Although human epidermal growth factor receptor 2 (HER2) positive or estrogen receptor (ER) positive breast cancers are treated with clinically validated anti-HER2 or anti-estrogen therapies, intrinsic and acq...

    Authors: Qing Cheng, Jeffrey T Chang, Joseph Geradts, Leonard M Neckers, Timothy Haystead, Neil L Spector and H Kim Lyerly
    Citation: Breast Cancer Research 2012 14:R62
    Content type: Research article Published on:

  8. Uncontrolled proliferation and increased motility are hallmarks of neoplastic cells, therefore markers of proliferation and motility may be valuable in assessing tumor progression and prognosis. MCM2 is a memb...

    Authors: Jun Yang, Nithya Ramnath, Kirsten B Moysich, Harold L Asch, Helen Swede, Sadir J Alrawi, Joel Huberman, Joseph Geradts, John SJ Brooks and Dongfeng Tan
    Citation: BMC Cancer 2006 6:203
    Content type: Research article Published on:

  9. Despite improvements in adjuvant therapy, late systemic recurrences remain a lethal consequence of both early- and late-stage breast cancer. A delayed recurrence is thought to arise from a state of tumor dorma...

    Authors: Qing Cheng, Jeffrey T Chang, William R Gwin, Jun Zhu, Stefan Ambs, Joseph Geradts and H Kim Lyerly
    Citation: Breast Cancer Research 2014 16:407
    Content type: Research article Published on:

  10. Evidence suggests that alterations in estrogen signaling pathways, including estrogen receptor-α (ER-α), occur during breast cancer development. A point mutation in ER-α (nucleotide A908G), producing an amino ...

    Authors: Kathleen Conway, Eloise Parrish, Sharon N Edmiston, Dawn Tolbert, Chiu-Kit Tse, Joseph Geradts, Chad A Livasy, Harsharan Singh, Beth Newman and Robert C Millikan
    Citation: Breast Cancer Research 2005 7:R871
    Content type: Research article Published on:

  11. Chemotherapy remains the only available treatment for triple-negative (TN) breast cancer, and most patients exhibit an incomplete pathologic response. Half of patients exhibiting an incomplete pathologic respo...

    Authors: Shenduo Li, Sturgis Payne, Fang Wang, Peter Claus, Zuowei Su, Jeffrey Groth, Joseph Geradts, Gustaaf de Ridder, Rebeca Alvarez, Paul Kelly Marcom, Salvatore V. Pizzo and Robin E. Bachelder
    Citation: Breast Cancer Research 2015 17:91
    Content type: Research article Published on:

  12. Spatial heterogeneity in biomarker expression may impact breast cancer classification. The aims of this study were to estimate the frequency of spatial heterogeneity in biomarker expression within tumors, to i...

    Authors: Emma H. Allott, Joseph Geradts, Xuezheng Sun, Stephanie M. Cohen, Gary R. Zirpoli, Thaer Khoury, Wiam Bshara, Mengjie Chen, Mark E. Sherman, Julie R. Palmer, Christine B. Ambrosone, Andrew F. Olshan and Melissa A. Troester
    Citation: Breast Cancer Research 2016 18:68
    Content type: Research article Published on: